{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "66-year-old woman diagnosed with metastatic adenocarcinoma of the right lung (T2N0M1c) with ipsilateral pleural and diffuse bone spread.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C34.9",
              "label": "Malignant neoplasm of unspecified part of bronchus or lung",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "C79.51",
              "label": "Secondary malignant neoplasm of bone",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "C78.2",
              "label": "Secondary malignant neoplasm of pleura",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Initial treatment with carboplatin/pemetrexed chemotherapy resulted in a partial remission after two cycles, followed by pemetrexed maintenance.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0007074",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C0976082",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "C0976082",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "ALK rearrangement detected by fluorescence in situ hybridization (FISH). RNA next-generation sequencing (NGS) of the tumor identified transcripts of KLC1exon 9 fused with ALKexon 20 (K9\u2013A20).",
        "clinical_data": {
          "labs": [
            {
              "test": "Fluorescence in situ hybridization",
              "finding": "ALK rearrangement detected",
              "modality": "FISH"
            },
            {
              "test": "RNA next-generation sequencing",
              "finding": "KLC1exon 9 fused with ALKexon 20",
              "modality": "NGS",
              "body_part": "tumor"
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "ctDNA analysis from longitudinal blood plasma samples confirmed KLC1-ALK translocation with breakpoints in KLC1 intron 9 and ALK intron 19. Plasma sample during partial remission (after 2 cycles carboplatin/pemetrexed) showed ALK fusion variant allele frequency (VAF) of 0.09% and no ALK SNVs. Serum sample showed CEA 39.52 ng/\u00b5L and CYFRA 21-1 0.53 ng/\u00b5L.",
        "clinical_data": {
          "labs": [
            {
              "test": "C0009264",
              "value": "39.52",
              "unit": "ng/\u00b5L"
            },
            {
              "test": "CYFRA 21-1",
              "value": "0.53",
              "unit": "ng/\u00b5L"
            }
          ],
          "diagnoses": [
            {
              "code": "ALK",
              "label": "ALK fusion variant",
              "status": "active"
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Two months after pemetrexed maintenance, chest CT showed progression of primary tumor and pleural effusion. Brain MRI detected new cerebral metastases.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Chest CT",
              "body_part": "chest",
              "modality": "CT",
              "finding": "progression of primary tumor and pleural effusion",
              "date": null
            },
            {
              "type": "Brain MRI",
              "body_part": "brain",
              "modality": "MRI",
              "finding": "new cerebral metastases",
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "KLC1\u2013ALK fusion VAF rose to 6.25%. Tumor protein markers CEA and CYFRA 21\u20131 also increased.",
        "clinical_data": {
          "labs": [
            {
              "test": "C0009262",
              "value": "6.25",
              "unit": "%",
              "flag": "abnormal"
            }
          ],
          "diagnoses": [
            {
              "code": "C0007106",
              "label": "Cancer",
              "status": "active"
            }
          ]
        }
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "Second-line treatment with crizotinib (250 bid) was initiated, resulting in tumor shrinkage of ~40% as determined by radiological imaging. Retrospective analysis showed fusion VAF of 4.4%. ctDNA analysis identified four distinct secondary mutations in the kinase domain of the ALK gene: ALKp.F1174C, ALKp. F1174L, ALKp.G1269A.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0886439",
              "dosage": "250",
              "frequency": "bid",
              "modality": "oral",
              "indication": "Neoplasm",
              "start_date": null,
              "end_date": null
            }
          ],
          "imaging": [
            {
              "type": "Radiological imaging",
              "body_part": null,
              "modality": null,
              "finding": "tumor shrinkage of ~40%",
              "impression": null,
              "date": null
            }
          ],
          "labs": [
            {
              "test": "ctDNA analysis",
              "value": "ALK mutations identified",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            }
          ]
        }
      }
    },
    {
      "id": "N8",
      "label": "Step 8",
      "customData": {
        "node_id": "H",
        "node_step_index": 8,
        "content": "Whole-brain radiotherapy with 30 Gy (10 fractions of 3 Gy) was administered.",
        "clinical_data": {
          "procedures": [
            {
              "name": "Whole brain radiation therapy",
              "approach": "other",
              "date": null,
              "location": "brain",
              "performed_by": null,
              "outcome": null
            }
          ]
        }
      }
    },
    {
      "id": "N9",
      "label": "Step 9",
      "customData": {
        "node_id": "I",
        "node_step_index": 9,
        "content": "Clinical and radiological follow-up three months after whole-brain radiotherapy indicated stable disease, and crizotinib treatment was continued.",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0886439",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "imaging": [
            {
              "type": "C0205098",
              "body_part": "C0008625",
              "modality": null,
              "finding": "stable disease",
              "impression": null,
              "date": null
            }
          ],
          "procedures": [
            {
              "name": "C0043166",
              "approach": null,
              "date": null,
              "location": null,
              "performed_by": null,
              "outcome": null
            }
          ]
        }
      }
    },
    {
      "id": "N10",
      "label": "Step 10",
      "customData": {
        "node_id": "J",
        "node_step_index": 10,
        "content": "Plasma sample taken 3 weeks after the last radiation dose revealed rising VAFs of the fusion KLC1\u2013ALK (8.01%) and four secondary ALK variants, the most abundant of which was ALKp.F1174 (c.3522C>G with 3.26% VAF. CEA and CYFRA 21\u20131 concentrations were also elevated.",
        "clinical_data": {
          "labs": [
            {
              "test": "C0009199",
              "value": "elevated",
              "unit": null,
              "flag": "abnormal"
            },
            {
              "test": "CYFRA 21-1",
              "value": "elevated",
              "unit": null,
              "flag": "abnormal"
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "KLC1-ALK fusion",
              "status": "active"
            },
            {
              "code": null,
              "label": "ALK variant ALKp.F1174",
              "status": "active"
            }
          ]
        }
      }
    },
    {
      "id": "N11",
      "label": "Step 11",
      "customData": {
        "node_id": "K",
        "node_step_index": 11,
        "content": "One month later, multilocular disease progression occurred, with multiple new lung and bone metastases as confirmed by PET-CT.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Metastasis",
              "body_part": "Lung",
              "modality": "PET-CT",
              "finding": "Multiple new lung metastases",
              "impression": "Multilocular disease progression",
              "date": null
            },
            {
              "type": "Metastasis",
              "body_part": "Bone",
              "modality": "PET-CT",
              "finding": "Multiple new bone metastases",
              "impression": "Multilocular disease progression",
              "date": null
            }
          ],
          "diagnoses": [
            {
              "code": "C0205424",
              "label": "Disease Progression",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N12",
      "label": "Step 12",
      "customData": {
        "node_id": "L",
        "node_step_index": 12,
        "content": "Retrospective molecular reassessment with liquid biopsy showed steadily high VAFs. Protein markers rose further (CEA: >155 ng/\u00b5L, CYFRA 21\u20132: >200 ng/\u00b5L).",
        "clinical_data": {
          "labs": [
            {
              "test": "C0007682",
              "value": ">155",
              "unit": "ng/\u00b5L",
              "flag": "abnormal"
            },
            {
              "test": "CYFRA 21-1",
              "value": ">200",
              "unit": "ng/\u00b5L",
              "flag": "abnormal"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Initiation of carboplatin/pemetrexed chemotherapy for metastatic adenocarcinoma of the right lung (T2N0M1c) with ipsilateral pleural and diffuse bone spread. The treatment resulted in a partial remission after two cycles, followed by pemetrexed maintenance."
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Detection of ALK rearrangement by FISH and identification of KLC1exon 9 fused with ALKexon 20 (K9\u2013A20) transcripts via RNA NGS of the tumor, following initial treatment with carboplatin/pemetrexed chemotherapy resulting in a partial remission after two cycles, followed by pemetrexed maintenance.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [
            "C0005941"
          ],
          "change_type": "addition",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "ctDNA analysis from longitudinal blood plasma samples confirmed KLC1-ALK translocation with breakpoints in KLC1 intron 9 and ALK intron 19. Plasma sample during partial remission (after 2 cycles carboplatin/pemetrexed) showed ALK fusion variant allele frequency (VAF) of 0.09% and no ALK SNVs. Serum sample showed CEA 39.52 ng/\u00b5L and CYFRA 21-1 0.53 ng/\u00b5L.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [
            "C0005941"
          ],
          "change_type": "addition",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Progression of primary tumor and pleural effusion on chest CT, and new cerebral metastases detected on brain MRI, two months after pemetrexed maintenance.",
        "transition_event": {
          "trigger_type": "spontaneous",
          "trigger_entities": [
            "C0009402",
            "C0022841"
          ],
          "change_type": "progression",
          "target_domain": "imaging"
        }
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Increase in KLC1\u2013ALK fusion VAF to 6.25% and elevation of tumor protein markers CEA and CYFRA 21\u20131, following progression of primary tumor and pleural effusion on chest CT, and new cerebral metastases detected on brain MRI.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [
            "C0009262"
          ],
          "change_type": "escalation",
          "target_domain": "lab"
        }
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Initiation of second-line treatment with crizotinib (250 bid), resulting in tumor shrinkage of ~40% as determined by radiological imaging. Retrospective analysis showed fusion VAF of 4.4%. ctDNA analysis identified four distinct secondary mutations in the kinase domain of the ALK gene: ALKp.F1174C, ALKp. F1174L, ALKp.G1269A.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0886439"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N7",
      "to": "N8",
      "data": {
        "edge_id": "G_to_H"
      }
    }
  ]
}